Back grey_arrow_rt.gif
 
 
Janssen New HIV Electronic/Web-Based Records/E-Prescribing
 
 
  Janssen Diagnostics:

We are pleased to announce that our HIV/AIDS specific electronic record has received ONC-ATCB Certification. This means that providers who use the record could be eligible for government grants as part of the stimulus act. Designed Specifically for the HIV/AIDS Treatment Community, AVIGA™ Includes E-prescribing, Advanced Data Exporting to CAREWare and Clinical Quality Measuring Capabilities.

Janssen Diagnostic's AVIGA™ Receives Complete ONC-ATCB Certification by Drummond Group

Designed Specifically for the HIV/AIDS Treatment Community, AVIGA™ Includes E-prescribing, Advanced Data Exporting to CAREWare and Clinical Quality Measuring Capabilities

Raritan, US, July 18, 2012: Janssen Diagnostics Inc. today announced that its web based electronic health record (EHR), AVIGA™ has received Complete EHR Ambulatory Certification. This designation officially deems the EHR capable of enabling providers to qualify for funding under the American Recovery and Reinvestment Act (ARRA)[1]. Tested and certified under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Testing and Certification Body (ONC-ATCB) program, the EHR software is 2011/2012 compliant in accordance with the criteria adopted by the Secretary of Health and Human Services.

"This certification is a significant milestone for our user community, and for Janssen Diagnostics," said David Rebey, US Team Leader, Infectious Diseases and HIT, Janssen Diagnostics, Inc. He added, "It is important that our customers have an EHR option that not only qualifies for federal incentives, but also meets their specific needs in managing the care of people living with HIV, as well as specific State and Federal reporting requirements. We believe that AVIGA™ will be important in helping physicians improve outcomes for people living with HIV"

Drummond Group's ONC-ATCB 2011/2012 certification program tests and certifies that EHRs meet the meaningful use criteria for either eligible provider or hospital technology. In turn, healthcare providers using the EHR systems of certified vendors are qualified to receive federal stimulus monies upon demonstrating meaningful use of the technology - a key component of the federal government's initiative to improve clinical care delivery through the adoption and effective use of EHRs by U.S. healthcare providers.

AVIGA™ allows users to collect, manage and analyze patient data from physicians, pharmacies, labs and clinics. The software's HIV/AIDS specific functionality offers health care providers an analytical module, and the capability to graph such clinical indicators as viral load and CD4 trends against antiretroviral therapy and integrate longitudinal resistance profiles.

To meet full certification requirements, AVIGA™ unveiled new features including, e-prescribing, the ability for users to measure meaningful use quality metrics, submit a patient's immunization history to the appropriate immunization registry, and confirm that medications being prescribed are listed on customized drug formularies. In addition users are able to generate the Ryan White HIV/AIDS Services Reports (RSR client level data) and export it directly into CAREWare, the government's software used to manage HIV/AIDS information, thus eliminating the need for duplicative data entry. The RSR Report is a requirement for providers who receive funding from the Ryan White Care Act.

The AVIGA family of products is at the forefront of HIV/AIDS EHR technology and includes AVIGA REPORTER™, a data-reporting module that will primarily serve as a reporting and querying tool for both local and federal data reporting, including requirements for Ryan White Care Act funding. This module can interface with other commercial EHRs and software applications, specifically capturing and configuring medical information necessary for HIV reporting or research.

###

AVIGA™ 2.0 is 2011/2012 compliant and has been certified by an ONC-ATCB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services or guarantee the receipt of incentive payments. The ONC certification number is 05172012-4394-6 and was granted on May 17, 2012. The clinical quality measures to which AVIGA™ 2.0 has been certified include: NQF001, NQF0002, NQF0004, NQF0013, NQF0018, NQF0024, NQF0027, NQF0028,NQF0031, NQF0032, NQF0033, NQF0034, NQF0036, NQF0038, NQF0041, NQF0043, NQF0047, NQF0052, NQF0055, NQF0056, NQF0059, F0061, NQF0062, NQF0064, NQF0067, NQF0068, NQF0070, NQF0073, NQF0074, NQF0075, NQF0084, NQF0086, NQF0088, NQF0089, NQF0105, NQF0385, NQF0387, NQF0389, NQF0421, NQF0575. The additional software that AVIGA™ 2.0 relied upon to demonstrate compliance includes: popHealth and MIRTH Connect.

About Janssen Diagnostics

Janssen Diagnostics BVBA is a global, Johnson & Johnson Company based in Beerse, Belgium and Raritan, NJ, United States (Janssen Diagnostics, Inc.) committed to personalizing healthcare outcomes as a partner to the healthcare industry worldwide.

The Janssen Diagnostics team is dedicated to improving patients' lives, one by one, by making true personalized care the cornerstone of our future healthcare system. We aim to influence current thinking beyond drug treatment and grow as a true solution provider. The Janssen legacy of excellence in Infectious Diseases, Oncology, Neuroscience, Cardiovascular Diseases and Immunology will continue to drive innovation in the fields of Diagnostics Solutions and Health Information Technology, enabling us to reach our goal: to develop care solutions that cater to each individual's need.

[1] DISCLAIMER: THE INFORMATION CONTAINED IN THIS RELEASE IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENTS NO STATEMENT, PROMISE OR GUARANTEE BY JANSSEN DIAGNOSTICS CONCERNING RECEIPT OR PAYMENT OF GOVERNMENT INCENTIVES. JANSSEN DIAGNOSTICS STRONGLY URGES THAT YOU CONSULT WITH YOUR COUNSEL FOR ADVICE ON INCENTIVE ELIGIBILITY.

Media Contacts

Frederik Wittock

Janssen Global Services, LLC

+32 14 60 57 24 or fwittock@its.jnj.com

Diane Pressman

Janssen Global Services, LLC

908-927-6171 or dpressm1@its.jnj.com

Customer Contact (US):

Michael Tobin

Executive Director Policy and Payment

Janssen Diagnostics, Inc.

631-786-4720 or mtobin2@its.jnj.com

 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org